 AIM ImmunoTech Inc. said it has signed a signed clinical trial agreement for a Phase 2a Human Challenge Trial HCT with hVIVO for a Phase 2a Human Challenge Trial HCT to test the companys flagship drug Ampligen as a potential intranasal prophylactic using a human rhinovirus HRV-16, a common cold virus and influenza A virus H3N2. 